Ingersoll Rand reports Q1 2026 results on April 29 with options positioning at its most defensive in months, even as short sellers quietly reduce exposure ahead of the print.
The clearest signal into earnings is in the options market. The put/call ratio has climbed to 0.41, nearly two standard deviations above its 20-day mean of 0.35 — the most elevated defensive reading in the recent window. That shift arrived this week alongside a sharp pullback: the stock fell 3.4% on Tuesday and is down 4.3% on the week to $81.19, having trimmed a 2.2% monthly gain. The PCR had been running in a narrow band around 0.31 for most of April before spiking over the last three sessions, suggesting fresh hedging demand rather than structural pessimism.
Short interest tells a different story. Bears have been trimming, not building. SI % of FF has eased to 4.3% from a mid-April peak near 4.6%, with the most recent daily reading down a further 1.4%. Borrow costs remain negligible at 0.50%, and the lending market is comfortably loose — availability is ample relative to current short positioning. Days to cover runs at 5.5 on the official FINRA reading, well below distress territory. The ORTEX short score of 43.1 has drifted lower over the past two weeks from 45.7, consistent with short sellers reducing rather than pressing the trade.
The bull-bear debate heading into Q1 centres on margin trajectory and volume resilience. Bulls point to Ingersoll Rand's $7.2 billion revenue base, high-teens Americas order growth, and a book-to-bill above 1x that suggests demand held up into early 2026. Bears reference the trajectory from Q2 2025, when the company cut organic sales guidance on tariff-related pricing headwinds and EBITDA margins compressed by 40 basis points year-on-year. Analysts have trimmed targets broadly since early April — Citigroup moved from $117 to $113 while maintaining Buy, Wells Fargo cut from $110 to $90 while keeping Overweight — bringing the consensus mean target to $98.93, roughly 22% above the current price. That gap reflects retained conviction on the longer-term setup, but the target reductions signal the Street is accounting for macro drag. The stock trades at a PE of 23.1x and EV/EBITDA of 16.6x, multiples that price in a recovery in organic volume growth.
One ownership detail is worth noting. T. Rowe Price added over 6.3 million shares in Q1 — by far the largest move among top holders — lifting its stake to 7.8% of shares outstanding. That signals at least one large active manager used the recent weakness to build. The CEO, Vicente Reynal, sold $2.7 million in shares on April 13 at $88, following a larger $11.1 million sale in early March, though both transactions carry a low significance score and are consistent with scheduled programme selling rather than a directional view.
The Q1 print is therefore less about whether IR can grow and more about whether management can hold the margin line and defend organic guidance against a tariff-disrupted demand environment — the same question the market penalised sharply last summer, and the one that will determine whether the analyst consensus gap begins to close.
See the live data behind this article on ORTEX.
Open IR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
